Treatment of diabetes and heart failure: joint forces

Affiliations

¹ Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden National Heart and Lung Institute, Imperial College, London, UK karl.swedberg@gu.se.
² Department of Medicine K2, Karolinska Institute, Stockholm, Sweden.

Editorial

Karl Swedberg et al. Eur Heart J. 2016.

. 2016 May 14;37(19):1535-7.

doi: 10.1093/eurheartj/ehw039. Epub 2016 Feb 22.

¹ Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden National Heart and Lung Institute, Imperial College, London, UK karl.swedberg@gu.se.
² Department of Medicine K2, Karolinska Institute, Stockholm, Sweden.

Erratum in

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Fitchett D, et al. Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26. Eur Heart J. 2016. PMID: 26819227 Free PMC article.

No abstract available

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Fitchett D, et al. Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26. Eur Heart J. 2016. PMID: 26819227 Free PMC article.